Rituximab-based treatments followed by adoptive cellular immunotherapy for biopsy-proven EBV-associated post-transplant lymphoproliferative disease in recipients of allogeneic hematopoietic stem cell transplantation

OncoImmunology

Volumn 5, Issue 5, 2016, Pages

  Jiang, Xinmiao ^a   Xu, Lanping ^b   Zhang, Yu ^a   Huang, Fen ^a   Liu, Daihong ^b   Sun, Jin ^a   Song, Chaoyang ^c   Liang, Xinquan ^d   Fan, Zhiping ^a   Zhou, Hongsheng ^a   Dai, Min ^a   Liu, Can ^a   Jiang, Qianli ^a   Xu, Na ^a   Xuan, Li ^a   Wu, Meiqing ^a   Huang, Xiaojun ^b   Liu, Qifa ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b PEKING UNIVERSITY   (China)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

^d THE FIRST PEOPLE S HOSPITAL OF CHENZHOU   (China)

Author keywords

Adoptive cellular immunotherapy; Donor lymphocyte infusion; EBV; EBV CTL; Hematopoietic stem cell transplantation; PTLD; Relapse; Rituximab

Indexed keywords

CYCLOSPORIN A; GRANULOCYTE COLONY STIMULATING FACTOR; MEPREDNISONE; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; CHEMOTHERAPY; CHILD; CHRONIC MYELOID LEUKEMIA; DISEASE COURSE; EPSTEIN BARR VIRUS; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNE DEFICIENCY; IN SITU HYBRIDIZATION; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MYCOSIS; MYELODYSPLASTIC SYNDROME; PHASE 2 CLINICAL TRIAL; PNEUMONIA; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION;

EID: 84975883647     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1139274     Document Type: Article

References (47)

1. J.Styczynski, H.Einsele, L.Gil, P.Ljungman. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Transpl Infect Dis 2009; 11:383-92; PMID:19558376; http://dx.doi.org/10.1111/j.1399-3062.2009.00411.x
2. S.Choquet, V.Leblond, R.Herbrecht, G.Socie, A.M.Stoppa, P.Vandenberqhe, A.Fischer, F.Morschhauser, G.Salles, W.Feremans et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood 2006; 107:3053-7; PMID:16254143; http://dx.doi.org/10.1182/blood-2005-01-0377
3. A.H.Blaes, B.A.Peterson, N.Bartlett, D.L.Dunn, V.A.Morrison. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial. Cancer 2005; 104:1661-7; PMID:16149091; http://dx.doi.org/10.1002/cncr.21391
4. S.Choquet, S.Oertel, V.LeBlond, H.Riess, N.Varoqueaux, B.Dörken, R.Trappe. Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution. Ann Hematol 2007; 86:599-607; PMID:17522862; http://dx.doi.org/10.1007/s00277-007-0298-2
5. B.Savoldo, C.M.Rooney, R.E.Quiros-Tejeira, Y.Caldwell, H.J.Wagner, T.Lee, M.J.Finegold, G.Dotti, H.E.Heslop, J.A.Goss. Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease. Am J Transplant 2005; 5:566-72; PMID:15707412; http://dx.doi.org/10.1111/j.1600-6143.2004.00693.x
6. Z.P.Fang, X.F.Yu, Q.F.Liu. Post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation. NatI Med J China 2006; 86:2975-7
7. H.E.Heslop, K.S.Slobod, M.A.Pule, G.A.hale, C.A.Smith, C.M.Bollard, H.Liu, M.F.Wu, R.J.Rochester et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010; 115:925-35; PMID:19880495; http://dx.doi.org/10.1182/blood-2009-08-239186
8. J.Styczynski, H.Einsele, L.Gil, P.Ljungman. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Transpl Infect Dis 2009; 11:383-92; PMID:19558376; http://dx.doi.org/10.1111/j.1399-3062.2009.00411.x
9. E.Doubrovina, B.Oflaz-Sozmen, S.E.Prockop, N.A.kernan, S.Abramson, J.Teruya-Feldstein, C.Hedvat, J.F.Chou, G.Heller, J.N.Barker et al. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood 2012; 119:2644-56; PMID:22138512; http://dx.doi.org/10.1182/blood-2011-08-371971
10. E.B.Papadopoulos, M.Ladanyi, D.Emanuel, S.Mackinnon, F.Boulad, M.H.Carabasi, H.Castro-Malaspina, B.H.Childs, A.P.Gillio, T.N.Small et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994; 330:1185-91; PMID:8093146; http://dx.doi.org/10.1056/NEJM199404283301703
11. J.Styczynski, P.Reusser, H.Einsele, R.de la Camara, C.Cordonnier, K.N.Ward, P.Ljungman, D.Engelhard. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant 2009; 43:757-70; PMID:19043458; http://dx.doi.org/10.1038/bmt.2008.386
12. E.Klyuchnikov, E.Holler, M.Bornhäuser, G.Kobbe, A.Nagler, A.Shimoni, C.Könecke, C.Wolschke, U.Bacher, A.R.Zander et al. Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced-intensity allografting. Br J Haematol 2012; 159:172-81; PMID:22909192; http://dx.doi.org/10.1111/bjh.12013
13. A.M.Evens, K.A.David, I.Helenowski, B.Nelson, D.Kaufman, S.M.kircher, A.Gimelfarb, E.Hattersley, L.A.Mauro, B.Jjovanovic et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol 2010; 28:1038-46; PMID:20085936; http://dx.doi.org/10.1200/JCO.2009.25.4961
14. H.A.Hou, M.Yao, J.L.Tang, Y.K.Chen, B.S.Ko, S.Y.Huang, H.F.Tien, H.H.Chang, M.Y.Lu, T.T.Lin et al. Poor outcome in post transplant lymphoproliferative disorder with pulmonary involvement after allogeneic hematopoietic SCT: 13 years' experience in a single institute. Bone Marrow Transplant 2009; 43:315-21; PMID:18836488; http://dx.doi.org/10.1038/bmt.2008.325
15. A.Faye, P.Quartier, Y.Reguerre, P.Lutz, A.S.Carret, A.Dehée, P.Rohrlich, M.Peuchmaur, A.Matthieu- Boué, A.Fischer et al. Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children. Br J Haematol 2001; 115:112-8; PMID:11722420; http://dx.doi.org/10.1046/j.1365-2141.2001.03041.x
16. A.C.Maximiano, R.A.Sanchez, S.D.I.B.Cantos, G.M.Mendez, I.S.Ronco, P.M.Provencio. Ocular relapse of primary brain lymphoma in immunocompetent patient, treated with intrathecal rituximab. Clin Transl Oncol 2010; 12:701-3; PMID:20947485; http://dx.doi.org/10.1007/s12094-010-0580-y
17. A.Kikuchi, H.Kawada, Y.Iwaki, S.Machida, T.Tsuchiya, R.Fukuda, T.Hotta. [Measurement of rituximab concentration in the cerebrospinal fluid in CNS lymphoma]. Rinsho Ketsueki 2004; 45:1255-7; PMID:15678918
18. D.K.Bonney, E.E.Htwe, A.Turner, A.Kelsey, A.Shabani, S.Hughes, I.Hughes, R.F.Wynn. Sustained response to intrathecal rituximab in EBV associated Post-transplant lymphoproliferative disease confined to the central nervous system following haematopoietic stem cell transplant. Pediatr Blood Cancer 2012; 58:459-61; PMID:21584931; http://dx.doi.org/10.1002/pbc.23134
19. S.J.Stevens, E.A.Verschuuren, I.Pronk, W.van Der Bij, M.C.Harmsen, T.H.The, C.J.Meijer, A.J.van Den Brule, J.M.Middeldorp. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood 2001; 97:1165-71; PMID:11222357; http://dx.doi.org/10.1182/blood.V97.5.1165
20. K.R.Rai. Therapeutic potential of new B cell-targeted agents in the treatment of elderly and unfit patients with chronic lymphocytic leukemia. J Hematol Oncol 2015; 8:85; PMID:26170206; http://dx.doi.org/10.1186/s13045-015-0165-x
21. A.Novero, P.M.Ravella, Y.Chen, G.Dous, D.Liu. Ibrutinib for B cell malignancies. Exp Hematol Oncol 2014; 3:4; PMID:24472371; http://dx.doi.org/10.1186/2162-3619-3-4
22. J.Wu, J.Fu, M.Zhang, D.Liu. Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia. J Hematol Oncol 2015; 8:104; PMID:26337639; http://dx.doi.org/10.1186/s13045-015-0195-4
23. A.Clavert, P.Chevallier, T.Guillaume, J.Delaunay, S.Le Gouill, B.Mahe, V.Dubruille, T.Gastinne, N.Blin, P.Moreau et al. Safety and efficacy of rituximab in steroid-refractory chronic GVHD. Bone Marrow Transplant 2013; 48:734-6; PMID:23085828; http://dx.doi.org/10.1038/bmt.2012.203
24. R.Crocchiolo, L.Castagna, J.El-Cheikh, A.Helvig, S.Furst, C.Faucher, A.Vazquez, A.Granata, D.Coso, R.Bouabdallah et al. Prior rituximab administration is associated with reduced rate of acute GVHD after in vivo T-cell depleted transplantation in lymphoma patients. Exp Hematol 2011; 39:892-6; PMID:21703987; http://dx.doi.org/10.1016/j.exphem.2011.06.006
25. J.A.Kanakry, Y.L.Kasamon, J.Bolanos-Meade, I.M.Borrello, R.A.Brodsky, E.J.Fuchs, N.Ghosh, D.E.Gladstone, C.D.Gocke, C.A.Huff et al. Absence of Post-Transplantation Lymphoproliferative Disorder after Allogeneic Blood or Marrow Transplantation Using Post-Transplantation Cyclophosphamide as Graft-vs.-Host Disease Prophylaxis. Biol Blood Marrow Transplant 2013; 19:1514-7; PMID:23871780; http://dx.doi.org/10.1016/j.bbmt.2013.07.013
26. R.Trappe, S.Oertel, V.Leblond, P.Mollee, M.Sender, P.Reinke, R.Neuhaus, H.Lehmkuhl, H.A.Horst, G.Salles et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol 2012; 13:196-206; PMID:22173060; http://dx.doi.org/10.1016/S1470-2045(11)70300-X
27. S.Gupta, F.J.Fricker, R.P.Gonzalez-Peralta, W.B.Slayton, P.M.Schuler, V.R.Dharnidharka. Post-transplant lymphoproliferative disorder in children: recent outcomes and response to dual rituximab/low-dose chemotherapy combination. Pediatr Transplant 2010; 14:896-902; PMID:20642490; http://dx.doi.org/10.1111/j.1399-3046.2010.01370.x
28. H.E.Heslop, C.Y.Ng, C.Li, C.A.Smith, S.K.Loftin, R.A.Krance, M.K.Brenner, C.M.Rooney. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996; 2:551-5; PMID:8616714; http://dx.doi.org/10.1038/nm0596-551
29. K.M.Williams, R.E.Gress. Immune reconstitution and implications for immunotherapy following haematopoietic stem cell transplantation. Best Pract Res Clin Haematol 2008; 21:579-96; PMID:18790456; http://dx.doi.org/10.1016/j.beha.2008.06.003
30. M.D'Aveni, L.Aissi-Rothe, V.Venard, A.Salmon, A.Falenga, V.Decot, J.M.virion, Y.Wang, L.Clement, V.Latger-Cannard et al. The clinical value of concomitant Epstein Barr virus (EBV)-DNA load and specific immune reconstitution monitoring after allogeneic hematopoietic stem cell transplantation. Transpl Immunol 2011; 24:224-32; PMID:21440066; http://dx.doi.org/10.1016/j.trim.2011.03.002
31. L.Xu, Y.Zhang, G.Luo, Y.Li. The roles of stem cell memory T cells in hematological malignancies. J Hematol Oncol 2015; 8:113; PMID:26462561; http://dx.doi.org/10.1186/s13045-015-0214-5
32. I.Ricciardelli, M.P.Blundell, J.Brewin, A.Thrasher, M.Pule, P.J.Amrolia. Towards gene therapy for EBV-associated posttransplant lymphoma with genetically modified EBV-specific cytotoxic T cells. Blood 2014; 124:2514-22; PMID:25185261; http://dx.doi.org/10.1182/blood-2014-01-553362
33. D.Zeng, S.Dejbakhsh-Jones, S.Strober. Granulocyte colony-stimulating factor reduces the capacity of blood mononuclear cells to induce graft-versus-host disease: impact on blood progenitor cell transplantation. Blood 1997; 90:453-63; PMID:9207483
34. X.J.Huang, D.H.Liu, L.P.Xu, H.Chen, W.Han, K.Y.Liu, D.P.Lu. Prophylactic infusion of donor granulocyte colony stimulating factor mobilized peripheral blood progenitor cells after allogeneic hematological stem cell transplantation in patients with high-risk leukemia. Leukemia 2006; 20:365-8; PMID:16331281; http://dx.doi.org/10.1038/sj.leu.2403995
35. A.Vendramin, S.Gimondi, A.Bermema, P.longoni, S.Rizzitano, P.Corradini, C.Carniti. Graft monocytic myeloid-derived suppressor cell content predicts the risk of acute graft-versus-host disease after allogeneic transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood stem cells. Biol Blood Marrow Transplant 2014; 20:2049-55; PMID:25246295; http://dx.doi.org/10.1016/j.bbmt.2014.09.011
36. H.Liu, X.Zhai, Z.Song, J.Sun, Y.Xiao, D.Nie, Y.Zhang, F.Huang, H.Zhou, Z.Fan et al. Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study. J Hematol Oncol 2013; 6:15; PMID:23394705; http://dx.doi.org/10.1186/1756-8722-6-15
37. H.Zhang, J.Chen, W.Que. A meta-analysis of unrelated donor umbilical cord blood transplantation versus unrelated donor bone marrow transplantation in acute leukemia patients. Biol Blood Marrow Transplant 2012; 18:1164-73; PMID:22289799; http://dx.doi.org/10.1016/j.bbmt.2012.01.015
38. C.H.Yan, D.H.Liu, K.Y.Liu, L.P.Xu, Y.R.Liu, H.Chen, W.Han, Y.Wang, Y.Z.Qin, X.J.Huang et al. Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood 2012; 119:3256-62; PMID:22337715; http://dx.doi.org/10.1182/blood-2011-09-380386
39. P.Krishnamurthy, V.T.Potter, L.D.Barber, A.G.Kulasekararaj, Z.Y.Lim, R.M.Pearce, H.de Lavallade, M.Kenyon, R.M.Ireland, J.C.Marsh et al. Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes. Biol Blood Marrow Transplant 2013; 19:562-8; PMID:23266740; http://dx.doi.org/10.1016/j.bbmt.2012.12.013
40. Y.Lu, E.K.Waller. Dichotomous role of interferon-gamma in allogeneic bone marrow transplant. Biol Blood Marrow Transplant 2009; 15:1347-53; PMID:19822293; http://dx.doi.org/10.1016/j.bbmt.2009.07.015
41. K.Mucha, B.Foroncewicz, B.Ziarkiewicz-Wroblewska, M.Krawczyk, J.Lerut, L.Paczek. Post-transplant lymphoproliferative disorder in view of the new WHO classification: a more rational approach to a protean disease? Nephrol Dial Transplant 2010; 25:2089-98; PMID:20576725; http://dx.doi.org/10.1093/ndt/gfq231
42. N.L.Shapiro, C.G.Tang, N.Bhattacharyya. Association between Epstein-Barr virus seroconversion and immunohistochemical changes in tonsils of pediatric solid organ transplant recipients. Laryngoscope 2011; 121:1718-25; PMID:21792960; http://dx.doi.org/10.1002/lary.21871
43. W.Herr, E.Ranieri, W.Olson, H.Zarour, L.Gesualdo, W.J.Storkus. Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4(+) and CD8(+) T lymphocyte responses. Blood 2000; 96:1857-64; PMID:10961887
44. Q.Liu, L.Xuan, H.Liu, F.Huang, H.Zhou, Z.Fan, K.Zhao, M.Wu, L.Xu, X.Zhai et al. Molecular monitoring and stepwise preemptive therapy for Epstein-Barr virus viremia after allogeneic stem cell transplantation. Am J Hematol 2013; 88:550-5; PMID:23564232; http://dx.doi.org/10.1002/ajh.23452
45. B.D.Cheson, B.Pfistner, M.E.Juweid, R.D.Gascoyne, L.Specht, S.J.Horning, B.Coiffier, R.I.Fisher, A.Hagenbeek, E.Zucca et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25:579-86; PMID:17242396; http://dx.doi.org/10.1200/JCO.2006.09.2403
46. D.Przepiorka, D.Weisdorf, P.Martin, H.G.klingemann, P.Beatty, J.Hows, E.D.Thomas. Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15:825-8; PMID:7581076
47. K.M.Sullivan, H.M.Shulman, R.Storb, P.L.Weiden, R.P.Witherspoon, G.B.McDonald, M.M.Schubert, K.Atkinson, E.D.Thomas. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981; 57:267-76; PMID:7004534